Keytruda

Uses
Keytruda (Pembrolizumab) is a programmed death receptor (PD-1) blocking antibody. It is indicated in the treatment of certain forms of lung cancer and skin cancer. It is offered in a vial containing 50mg of Pembrolizumab in s suspension of L-histidine, polysorbate 80, sucrose, and water.

Dosage and Administration
Keytruda is usually prescribed at a dosage of 2mg/kg. This is administered by intravenous infusion over a period of thirty minutes. This should be repeated every three weeks until your doctor notices an improvement in the disease, or the levels in the body become too toxic.

Side effects
The most common side effects of Keytruda (Pembrolizumab) are tiredness, coughing, nausea, itchiness, rash, shortness of breath, reduce appetite, constipation or diarrhea, and joint pain.

Because of the way Keytruda works with your immune system to combat cancer, healthy organs and tissues can sometimes be attacked. This can cause problems some of which can be life-threating. Tell your doctor immediately if you notice any of the following problems:

Lung Problems (Pneumonitis): shortness of breath; chest pains; new or worsening cough.

Intestinal Problems (Colitis): diarrhea; more frequent bowel movements; black, tarry, sticky stools; stools with blood or mucous;sever abdominal pain or tenderness.

Liver Problems (Hepatitis): yellowing of the skin or whites of the eyes (jaundice); nausea or vomiting; abdominal pain on the right side; darker urine; reduced appetite; increased bleeding or bruising.

Hormone Gland Problems: increased heart rate; weight loss or weight gain; increased sweating; increased hunger or thirst; frequent urination; hair loss; chills; constipation; deeper voice; muscle aches; dizziness; fainting; headaches.

Kidney Problems: change in the amount of urination or the colour of the urine.

Problems with Other Organs: rash; eyesight changes; muscle pain; joint pain; weakness; anemia.

Precautions
Do not use Keytruda (Pembrolizumab) if you are pregnant or breast feeding. Pembrolizumab can cause damage to an unborn baby and it is not yet known if Keytruda is passed from a nursing mother through breast milk.